These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 16750166)

  • 1. Down-regulation of the NKG2D ligand MICA by the human cytomegalovirus glycoprotein UL142.
    Chalupny NJ; Rein-Weston A; Dosch S; Cosman D
    Biochem Biophys Res Commun; 2006 Jul; 346(1):175-81. PubMed ID: 16750166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein.
    Welte SA; Sinzger C; Lutz SZ; Singh-Jasuja H; Sampaio KL; Eknigk U; Rammensee HG; Steinle A
    Eur J Immunol; 2003 Jan; 33(1):194-203. PubMed ID: 12594848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity.
    Dunn C; Chalupny NJ; Sutherland CL; Dosch S; Sivakumar PV; Johnson DC; Cosman D
    J Exp Med; 2003 Jun; 197(11):1427-39. PubMed ID: 12782710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.
    Eisele G; Wischhusen J; Mittelbronn M; Meyermann R; Waldhauer I; Steinle A; Weller M; Friese MA
    Brain; 2006 Sep; 129(Pt 9):2416-25. PubMed ID: 16891318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.
    Song H; Kim J; Cosman D; Choi I
    Cell Immunol; 2006 Jan; 239(1):22-30. PubMed ID: 16630603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential NKG2D binding to highly related human NKG2D ligands ULBP2 and RAET1G is determined by a single amino acid in the alpha2 domain.
    Wittenbrink M; Spreu J; Steinle A
    Eur J Immunol; 2009 Jun; 39(6):1642-51. PubMed ID: 19424970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity.
    Diefenbach A; Hsia JK; Hsiung MY; Raulet DH
    Eur J Immunol; 2003 Feb; 33(2):381-91. PubMed ID: 12645935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein.
    Rölle A; Mousavi-Jazi M; Eriksson M; Odeberg J; Söderberg-Nauclér C; Cosman D; Kärre K; Cerboni C
    J Immunol; 2003 Jul; 171(2):902-8. PubMed ID: 12847260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.
    Armeanu S; Bitzer M; Lauer UM; Venturelli S; Pathil A; Krusch M; Kaiser S; Jobst J; Smirnow I; Wagner A; Steinle A; Salih HR
    Cancer Res; 2005 Jul; 65(14):6321-9. PubMed ID: 16024634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteolytic release of soluble UL16-binding protein 2 from tumor cells.
    Waldhauer I; Steinle A
    Cancer Res; 2006 Mar; 66(5):2520-6. PubMed ID: 16510567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium butyrate upregulates expression of NKG2D ligand MICA/B in HeLa and HepG2 cell lines and increases their susceptibility to NK lysis.
    Zhang C; Wang Y; Zhou Z; Zhang J; Tian Z
    Cancer Immunol Immunother; 2009 Aug; 58(8):1275-85. PubMed ID: 19139882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The inhibitory effects of synthetic short peptides, mimicking MICA and targeting at NKG2D receptors, on function of NK cells.
    Zhang B; Wei H; Zheng X; Zhang J; Sun R; Tian Z
    Peptides; 2005 Mar; 26(3):405-12. PubMed ID: 15652646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The herpesviral Fc receptor fcr-1 down-regulates the NKG2D ligands MULT-1 and H60.
    Lenac T; Budt M; Arapovic J; Hasan M; Zimmermann A; Simic H; Krmpotic A; Messerle M; Ruzsics Z; Koszinowski UH; Hengel H; Jonjic S
    J Exp Med; 2006 Aug; 203(8):1843-50. PubMed ID: 16831899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MCMV glycoprotein gp40 confers virus resistance to CD8+ T cells and NK cells in vivo.
    Krmpotić A; Busch DH; Bubić I; Gebhardt F; Hengel H; Hasan M; Scalzo AA; Koszinowski UH; Jonjić S
    Nat Immunol; 2002 Jun; 3(6):529-35. PubMed ID: 12021778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracellular retention of the MHC class I-related chain B ligand of NKG2D by the human cytomegalovirus UL16 glycoprotein.
    Wu J; Chalupny NJ; Manley TJ; Riddell SR; Cosman D; Spies T
    J Immunol; 2003 Apr; 170(8):4196-200. PubMed ID: 12682252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MICA/NKG2D-mediated immunogene therapy of experimental gliomas.
    Friese MA; Platten M; Lutz SZ; Naumann U; Aulwurm S; Bischof F; Bühring HJ; Dichgans J; Rammensee HG; Steinle A; Weller M
    Cancer Res; 2003 Dec; 63(24):8996-9006. PubMed ID: 14695218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of NKG2D ligands and subsequent enhancement of NK cell-mediated lysis of cancer cells by arsenic trioxide.
    Kim JY; Bae JH; Lee SH; Lee EY; Chung BS; Kim SH; Kang CD
    J Immunother; 2008 Jun; 31(5):475-86. PubMed ID: 18463537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NKG2D and Related Immunoreceptors.
    Strong RK; McFarland BJ
    Adv Protein Chem; 2004; 68():281-312. PubMed ID: 15500864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell surface organization of stress-inducible proteins ULBP and MICA that stimulate human NK cells and T cells via NKG2D.
    Eleme K; Taner SB; Onfelt B; Collinson LM; McCann FE; Chalupny NJ; Cosman D; Hopkins C; Magee AI; Davis DM
    J Exp Med; 2004 Apr; 199(7):1005-10. PubMed ID: 15051759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Release of MICB molecules by tumor cells: mechanism and soluble MICB in sera of cancer patients.
    Salih HR; Goehlsdorf D; Steinle A
    Hum Immunol; 2006 Mar; 67(3):188-95. PubMed ID: 16698441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.